Clinical Lung Cancer
IF
3.55
Papers
2007
Papers 2231
1 page of 224 pages (2,231 results)
Newest
#1Nathan Kuehne (UHN: University Health Network)
#2Katrina Hueniken (UHN: University Health Network)H-Index: 4
Last. Adrian G. Sacher (UHN: University Health Network)H-Index: 9
view all 15 authors...
Abstract null null Introduction null Recent advances in small cell lung cancer (SCLC) treatments necessitate a better understanding of real-world health utility scores (HUS) in patients treated under current standards to facilitate robust pharmaco-economic assessments. null null null Methods null In this single institution cohort observational study, HUS were evaluated in patients with SCLC through EQ-5D questionnaires at outpatient visits (encounters). In addition, patients completed questionna...
Source
#1Toshio Fujino (Kindai University)H-Index: 5
#2Kenichi Suda (Kindai University)H-Index: 25
Last. Kazuto Nishio (Kindai University)H-Index: 86
view all 11 authors...
Abstract null null Background null MET exon 14 skipping mutation is a driver mutation in lung cancer and is highly enriched in pulmonary pleomorphic carcinomas (PPCs). Whether there is intra-tumor or inter-tumor heterogeneity in MET exon 14 skipping status or in co-occurring genetic alterations in lung cancers driven by MET exon 14 skipping is unknown. null null null Methods null We analyzed tumor specimens obtained from 23 PPC patients (10 autopsied and 13 surgically resected). MET exon 14 skip...
Source
#1Hai-Yan Tu (Peking Union Medical College)H-Index: 18
#2Yang-Si Li (SCUT: South China University of Technology)H-Index: 6
Last. Jie Huang (Peking Union Medical College)
view all 21 authors...
Abstract null null Background null Pleural effusion (PE) has been one of the promising sources of liquid biopsy in advanced lung cancer patients. However, its clinical utility is not widely accepted due to the lack of full estimation of its potential versus routine clinical samples. null null null Method null A total of 164 advanced lung cancer patients were enrolled with 164 matched tumor tissue and PE-cfDNA, 153 accompanied plasma and 63 null 1 PE-sDNA. null null null Result null PE-cfDNA disp...
Source
#1Zhonglin Hao (UK: University of Kentucky)
#2Janeesh Sekkath Veedu (UK: University of Kentucky)H-Index: 2
Extensive stage small cell lung cancer carries extremely poor prognosis and adding immune checkpoint inhibitor to platinum etoposide combination in first line only improved outcomes modestly. Once disease recurs, treatment response is only transient in nature. Various strategies that are being explored include dual checkpoint blockade, BiTE and CAR-T cell approaches. Immune checkpoint inhibitors are being combined with PARP inhibitors. Other approaches currently being investigated include liposo...
Source
#1Tadashi SakaguchiH-Index: 4
#2Yasumasa Kokubo (Mie University)H-Index: 17
Last. Osamu HatajiH-Index: 17
view all 10 authors...
Clinical Practice Points null null null null • null null Immune checkpoint inhibitor (ICI) therapy could exacerbate preexisting active autoimmune diseases (AIDs), and the presence of preexisting AIDs might be associated with a greater risk of developing new immune-related adverse events (irAEs). null null • null null The safety of ICIs for patients with Lambert-Eaton myasthenic syndrome (LEMS), a neuromuscular autoimmune disease known as a paraneoplastic syndrome mainly associated with small-cel...
Source
#1Masayuki Nakao (JFCR: Japanese Foundation for Cancer Research)H-Index: 11
#2Hisashi Saji (St. Marianna University School of Medicine)H-Index: 29
Last. Tomohiro Haruki (Tottori University)H-Index: 14
view all 13 authors...
INTRODUCTION The prognostic significance of mediastinal lymph node dissection (MLND) in elderly patients with non-small cell lung cancer (NSCLC) remains unclear. This post hoc analysis of a nationwide multicenter cohort study (JACS1303) evaluated the prognostic significance of MLND in octogenarians with NSCLC. MATERIALS AND METHODS We included 622 octogenarians with NSCLC who underwent lobectomy. The median follow-up duration was 41.1 months. We compared survival and perioperative outcomes betwe...
Source
#1Nathan Mynard (Cornell University)
#2Ashish Saxena (Cornell University)
Last. Giuseppe Giaccone (Cornell University)H-Index: 58
view all 11 authors...
Abstract null null Introduction null The COVID-19 pandemic reached New York City in early March 2020 resulting in an 11-week lockdown period to mitigate further spread. It has been well documented that cancer care was drastically affected as a result. Given New York City's early involvement, we attempted to identify any stage shift that may have occurred in the diagnoses of non-small cell lung cancer (NSCLC) at our institution as a result of these lockdowns. null null null Patients and Methods n...
Source
#1Fred R. Hirsch (ISMMS: Icahn School of Medicine at Mount Sinai)H-Index: 129
#2Jill Walker (AstraZeneca)H-Index: 17
Last. Ignacio I. Wistuba (University of Texas MD Anderson Cancer Center)H-Index: 115
view all 6 authors...
Existing approaches for cancer diagnosis are inefficient in the use of diagnostic tissue, and decision-making is often sequential, typically resulting in delayed treatment initiation. Future diagnostic testing needs to be faster and optimize increasingly complex treatment decisions. We envision a future where comprehensive testing is routine. Our approach, termed the "combiome," combines holistic information from the tumor, and the patient's immune system. The combiome model proposed here advoca...
Source
#1Yan Jin (Fudan University)H-Index: 7
#2Qianqian Xue (Fudan University)H-Index: 1
Last. Yuan Li (Fudan University)H-Index: 27
view all 7 authors...
Abstract null null Background null Programmed death ligand 1 (PD-L1) expression is the current standard biomarker used to predict non-smallcell lung cancer (NSCLC) response to immunotherapy. Gene expression signatures also seem to be related to the response to immunotherapy. Understanding the clinical and prognostic impact of molecular phenotype and tumor features on PD-L1 expression in NSCLC patients may improve the prediction of immunotherapy response. null null null Materials and Methods null...
Source
#1Joseph SeitlingerH-Index: 7
Last. Jonathan Spicer (McGill University)H-Index: 19
view all 11 authors...
Abstract null null Background null : We sought to evaluate prognostic value of neutrophil-to-lymphocyte ratio (NLR) in surgically resected non-small cell lung cancer (NSCLC) and its correlation to oncogenic drivers. null We retrospectively reviewed data of patients who underwent anatomic lung resection for NSCLC and whose mutational status was known, from 4 department of thoracic surgery, over the period 2008 to 2019. Primary endpoints were overall survival (OS) and time to recurrence (TTR). Cli...
Source
12345678910
Top fields of study
Surgery
Pathology
Oncology
Lung cancer
Chemotherapy
Cancer research
Medicine